Don't miss any news, subscribe to our press releases.
The program targets the protein vaccinia-related kinase 1 (VRK1), which is involved in the cell's response to DNA damage and control of cell division. Elevated levels of VRK1 are correlated with poorer survival in a variety of cancers. VRK1 has also been identified as a possible target protein in cancers that have low levels of the related protein VRK2, such as glioblastoma and neuroblastoma.
In August 2023, Sprint Bioscience licensed the global rights to the VRK1 program to Day One Biopharmaceuticals Inc.
Potential contract value: USD 316 million plus single-digit royalties on sales of a future drug from the program.